NasdaqCM - Nasdaq Real Time Price USD

Sonoma Pharmaceuticals, Inc. (SNOA)

Compare
2.5800
-0.0700
(-2.64%)
At close: January 13 at 4:00:00 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
13,547.0000
12,735.0000
13,272.0000
12,628.0000
18,629.0000
Cost of Revenue
8,329.0000
7,990.0000
8,795.0000
8,635.0000
12,070.0000
Gross Profit
5,218.0000
4,745.0000
4,477.0000
3,993.0000
6,559.0000
Operating Expense
9,494.0000
9,446.0000
9,047.0000
9,880.0000
10,008.0000
Operating Income
-4,276.0000
-4,701.0000
-4,570.0000
-5,887.0000
-3,449.0000
Net Non Operating Interest Income Expense
--
--
16.0000
-10.0000
4.0000
Other Income Expense
534.0000
-330.0000
-614.0000
479.0000
-457.0000
Pretax Income
-3,742.0000
-5,031.0000
-5,184.0000
-5,418.0000
-3,902.0000
Tax Provision
-56.0000
-196.0000
-33.0000
-332.0000
713.0000
Net Income Common Stockholders
-3,686.0000
-4,835.0000
-5,151.0000
-5,086.0000
-3,950.0000
Diluted NI Available to Com Stockholders
-3,686.0000
-4,835.0000
-5,151.0000
-5,086.0000
-3,950.0000
Basic EPS
-0.99
-10.60
-30.40
-38.40
-39.40
Diluted EPS
-0.99
-10.60
-30.40
-38.40
-39.40
Basic Average Shares
799.5000
454.5000
169.7000
132.6500
99.8000
Diluted Average Shares
799.5000
454.5000
169.7000
132.6500
99.8000
Total Operating Income as Reported
-4,276.0000
-4,701.0000
-4,570.0000
-5,887.0000
-3,449.0000
Total Expenses
17,823.0000
17,436.0000
17,842.0000
18,515.0000
22,078.0000
Net Income from Continuing & Discontinued Operation
-3,686.0000
-4,835.0000
-5,151.0000
-5,086.0000
-3,950.0000
Normalized Income
-3,686.0000
-4,835.0000
-5,151.0000
-5,904.8740
-4,715.0100
Interest Income
--
--
--
--
16.0000
Interest Expense
--
--
--
--
12.0000
Net Interest Income
--
--
16.0000
-10.0000
4.0000
EBIT
-4,276.0000
-4,701.0000
-4,570.0000
-5,887.0000
-3,449.0000
EBITDA
-4,116.0000
-4,525.0000
-4,445.0000
-5,701.0000
-3,222.0000
Reconciled Cost of Revenue
8,329.0000
7,990.0000
8,795.0000
8,635.0000
12,070.0000
Reconciled Depreciation
160.0000
176.0000
125.0000
186.0000
227.0000
Net Income from Continuing Operation Net Minority Interest
-3,686.0000
-4,835.0000
-5,151.0000
-5,086.0000
-4,615.0000
Total Unusual Items Excluding Goodwill
--
--
1.0000
873.0000
137.0000
Total Unusual Items
--
--
1.0000
873.0000
137.0000
Normalized EBITDA
-4,116.0000
-4,525.0000
-4,445.0000
-6,574.0000
-3,359.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0001
0.0003
Tax Effect of Unusual Items
--
--
--
54.1260
36.9900
3/31/2021 - 1/25/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SXTC China SXT Pharmaceuticals, Inc.
0.4220
-12.08%
 
AKAN Akanda Corp.
1.6300
+4.49%
 
BFRI Biofrontera Inc.
1.1300
+0.89%
 
CPIX Cumberland Pharmaceuticals Inc.
2.3300
0.00%
 
EXMT Anything Technologies Media, Inc.
0.0006
+20.00%
 
SBFM Sunshine Biopharma, Inc.
2.8900
-1.37%
 
CLSH CLS Holdings USA, Inc.
0.0320
0.00%
 
PROC Procaps Group S.A.
1.6300
+1.24%
 
PTPI Petros Pharmaceuticals, Inc.
0.3450
-8.27%
 
FFNTF 4Front Ventures Corp.
0.0090
+1.12%